Llwytho...
Metabolic Targets in Nonalcoholic Fatty Liver Disease
The prevalence and diagnosis of nonalcoholic fatty liver disease (NAFLD) is on the rise worldwide and currently has no FDA-approved pharmacotherapy. The increase in disease burden of NAFLD and a more severe form of this progressive liver disease, nonalcoholic steatohepatitis (NASH), largely mirrors...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Cell Mol Gastroenterol Hepatol |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Elsevier
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6698700/ https://ncbi.nlm.nih.gov/pubmed/31004828 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcmgh.2019.04.007 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|